Komori
Changes in Officers4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Changes in Representative Directors

Miyazawa Keiji (宮澤敬治) will become representative director, president and chief operating officer (COO), changing from director and head of the Research Division, while current representative director, president and COO Takehana Yasuo (竹花泰雄) will become an advisor. The formal decision is scheduled to be made at a Board of Directors meeting scheduled to be held on the same day as the Annual General Meeting of Shareholders.

Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Who is moving to which position

Resolved 24 April 2026

Incoming appointee

1 item
Scheduled Appointment Date23 June 2026. Formal approval is scheduled to be made at the Annual General Meeting of Shareholders scheduled for 23 June 2026 and at the Board of Directors meeting scheduled to be held on the same day.
Miyazawa Keiji (宮澤敬治)
Previous positionDirector and Head of the Research Division, and Director of KISSEI AMERICA, INC.
New positionRepresentative Director, President and Chief Operating Officer (COO)
生年月日 14 April 1967入社年 1993所有株式数 4,407 shares (record date not disclosed)

Departing officer

1 item
Date of departure23 June 2026
Takehana Yasuo (竹花泰雄)Next role stated
Former PositionRepresentative Director, President and Chief Operating Officer (COO)
New positionAdviser

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Whether the incumbent will remain in office (whether they will retain their position)

Appears that he will not remain on the Board of Directors

Shareholders’ meeting approvalRequired. Formal approval is scheduled to be made at the Annual General Meeting of Shareholders scheduled for 23 June 2026 and at the Board of Directors meeting scheduled to be held on the same day (proposal name not disclosed).
Reason for change

This is intended to strengthen the management structure to achieve the medium-term management plan Beyond 80, which began last April.

Who is moving to which position
ItemDetails
Resolution date24 April 2026
Scheduled Appointment Date23 June 2026. Formal approval is scheduled to be made at the Annual General Meeting of Shareholders scheduled for 23 June 2026 and at the Board of Directors meeting scheduled to be held on the same day.
Date of departure23 June 2026
Name of appointeeMiyazawa Keiji (宮澤敬治)
Appointee's new positionRepresentative Director, President and Chief Operating Officer (COO)
Appointee's previous positionDirector and Head of the Research Division, and Director of KISSEI AMERICA, INC.
Appointee's date of birth14 April 1967
Year the appointee joined the Company1993
Number of shares held by the appointee4,407 shares (record date not disclosed)
Name of departing officerTakehana Yasuo (竹花泰雄)
Former position of departing officerRepresentative Director, President and Chief Operating Officer (COO)
New position of departing officerAdviser
Whether the incumbent will remain in officeAppears that he will not remain on the Board of Directors
Reason for changeThis is intended to strengthen the management structure to achieve the medium-term management plan Beyond 80, which began last April.
Subject to Approval by the General Meeting of ShareholdersRequired. Formal approval is scheduled to be made at the Annual General Meeting of Shareholders scheduled for 23 June 2026 and at the Board of Directors meeting scheduled to be held on the same day (proposal name not disclosed).
Items this document does not state (6)
Reason for departureReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This is intended to strengthen the management structure to achieve the medium-term management plan Beyond 80, which began last April.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Changes in Representative Directors | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori